Screening for Femoral Head Osteonecrosis Following COVID-۱۹: Is It Worth It?
- سال انتشار: 1402
- محل انتشار: مجله استخوان و جراحی عمومی، دوره: 11، شماره: 12
- کد COI اختصاصی: JR_TABO-11-12_001
- زبان مقاله: انگلیسی
- تعداد مشاهده: 167
نویسندگان
Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
۱ Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran ۲ American Hip Institute, Chicago, Illinois, USA
UConn Health, Department of Orthopedic Surgery; Farmington, Connecticut, USA
Andrews Institute for Orthopedics and Sports Medicine; Gulf Breeze, FL, USA
Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
چکیده
Objectives: Based on WHO data, as of June ۲۰۲۲, there were ۵۳۲.۲ million confirmed COVID-۱۹ cases globally.In the initial phase of the COVID -۱۹ pandemic, patients experiencing critical illness marked by severe respiratorydistress were commonly subjected to corticosteroid treatment. Regrettably, the administration of exogenouscorticosteroids stands as the prevailing cause of ONFH. In the current narrative review, we aim to evaluate if activescreening should be utilized to diagnose post-COVID-۱۹ ONFH in its early stages.Methods: The databases for PubMed, CINAHL, and Science Direct were systematically queried in March ۲۰۲۲.The search terms were as follows: “COVID-۱۹”, “severe acute respiratory syndrome”, “coronavirus”, “systemicsteroid”, “corticosteroid”, “femoral head osteonecrosis”, “avascular necrosis”, or “steroid therapy.” The includedstudies for review were all required to be peer-reviewed studies in the English language with Reported complicationslinked to steroid therapy in COVID-۱۹ patients or potential connections to the development of ONFH in individualsrecovering from the novel coronavirus have been documented.Results: Systemic corticosteroids were frequently employed in managing critically ill COVID-۱۹ patients. The CDCreports up to June ۲۰۲۲ showed more than ۴.۸ million COVID-۱۹ hospitalizations in the US, with approximately overone million patients receiving steroids. In a study of ONFH after infection with COVID-۱۹, all patients had bilateralinvolvement. The average duration from the initiation of corticosteroid treatment to the onset of symptoms was ۱۳۲.۸days.Conclusion: In summary, a distinct correlation exists between the administration of steroids to individuals with COVID۱۹ and the subsequent risk of ONFH. Moreover, an elevated dosage and prolonged duration of steroid therapy inCOVID-۱۹ patients are associated with an increased likelihood of developing ONFH. Therefore, active screening forhigh-risk patients, that may have received systemic corticosteroid treatment during a COVID-۱۹ illness, may bereasonable. Level of evidence: IVکلیدواژه ها
COVID-۱۹, Osteonecrosis of femoral head, steroidاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.